ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KRAS
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KRAS
28
trial(s) found.
NCT06875310
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) (
CA239-0004
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3066 - Epping - Northern Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6027 - Joondalup - Joondalup Health Campus
NCT06804824
Advanced
Phase 1
Recruiting
A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors (
VVD-159642-01
)
HRAS G12C inhibitor
HRAS inhibitor
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
KRAS inhibitor
MEK inhibitor
NRAS G12C inhibitor
NRAS inhibitor
Sotorasib
Trametinib
cancer therapy
cancer therapy,HRAS G12C-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,MEK-targeting
cancer therapy,NRAS G12C-targeting
+ KRAS G12C/NRAS G12C/HRAS G12C inhibitor
Solid tumour
WA
6009 - Nedlands - Linear Clinical Research
NCT06764771
Advanced
Phase 1
Recruiting
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors (
CA234-0001
)
unknown drug class
+ KRAS G12C inhibitor
Cancer
QLD
4032 - Chermside - The Prince Charles Hospital
NCT06659341
Advanced
Phase 1
Recruiting
Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors
SOS1-KRAS inhibitor
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06619587
Advanced
Phase 1
Recruiting
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation (
GO45416
)
KRAS G12D inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06599502
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (
ALAFOSS-01
)
KRAS G12D inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06585488
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications (
BGB-53038-101
)
pan-KRAS inhibitor
Cancer
Colorectal cancer
Gastric cancer
Non-squamous non-small-cell lung cancer
Oesophageal adenocarcinoma
Pancreatic adenocarcinoma
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06497556
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
Krascendo-1
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06345729
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50% (
1084-004
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06343402
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study (
TBBO8520-101
)
KRAS G12C inhibitor
Colorectal adenocarcinoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06333951
Advanced
Phase 1
Recruiting
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
PRMT5 inhibitor
+ KRAS G12C/NRAS G12C/HRAS G12C inhibitor
Non-small cell lung cancer
Thoracic cancer
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06252649
Advanced
Phase 3
Recruiting
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) (
CodeBreaK-301
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06179160
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (
INCB161734-101
)
KRAS G12D inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NCT06119581
Advanced
Phase 3
Recruiting
SUNRAY-01
, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
placebo
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05789082
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (
Krascendo-170
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT05410145
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (
D3S-001-100
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)
NCT04956640
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors (
LOXO-RAS-20001
)
KRAS G12C inhibitor
Biliary tract cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04929223
Advanced
Phase 1
Recruiting
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (
WO42758
)
Atezolizumab
Bevacizumab
CDK7 inhibitor
Cetuximab
Divarasib
Inavolisib
KRAS G12C inhibitor
KRAS inhibitor
PI3K alpha inhibitor
SY-5609
Tiragolumab
anti-EGFR monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,CDK7-targeting
cancer therapy,EGFR-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ KRAS G12C inhibitor
Colorectal adenocarcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04613596
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (
CA239-0009
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3168 - Clayton - Monash Medical Centre (WITHDRAWN)
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT04449874
Advanced
Phase 1
Recruiting
A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (
GO42144
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04185883
Advanced
Phase 1
Recruiting
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
Sarcoma
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (TERMINATED)
ACTRN12622000973718
Advanced
Phase 2
Recruiting
SHERLOCK
: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-VEGF monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06024174
Advanced
Phase 1 / Phase 2
Terminated
Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors (
CA126-0015
)
KRAS G12C inhibitor
SHP2 inhibitor
anti-EGFR monoclonal antibody
Biliary tract cancer
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT05480865
Advanced
Phase 1
Terminated
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (
Argonaut
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
SHP2 inhibitor
Non-small cell lung cancer
Solid tumour
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - One Clinical Research
NCT05462717
Advanced
Phase 1
Active not recruiting
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (
RMC-6291-001
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
NCT05198934
Advanced
Phase 3
Active not recruiting
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (
CodeBreak300
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05054725
Advanced
Phase 2
Unknown
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies (
RMC-4630-03
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
SHP2 inhibitor
Non-small cell lung cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3630 - Shepparton - Goulburn Valley Health
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (23)
Terminated (2)
Active not recruiting (2)
Unknown (1)
Recruitment Country and State
NSW (24)
VIC (22)
SA (13)
WA (11)
QLD (8)
NZ (5)
ACT (2)
TAS (1)
Phase
Phase 1 (14)
Phase 1 / Phase 2 (5)
Phase 2 (2)
Phase 2 / Phase 3 (1)
Phase 3 (6)
Trial Type
Advanced (28)
Cancer Therapy Class
KRAS
100%
KRAS G12C
86%
PD-1/PD-L1
57%
PD-1
50%
EGFR
46%
HRAS G12C
36%
NRAS G12C
36%
VEGF
18%
SHP2
18%
KRAS G12D
11%
PD-L1
11%
MEK
7%
PI3Kalpha
7%
DPD
4%
orotate phosphoribosyltransferase
4%
PRMT5
4%
CDK7
4%
TIGIT
4%
CDK4
4%
CDK6
4%
ERBB2
4%
mTOR
4%
mTORC1
4%
FGFR
4%
FGFR1
4%
FGFR1/2/3
4%
FGFR2
4%
FGFR3
4%
FGFR4
4%
KIT
4%
PDGFR
4%
RET
4%
VEGFR
4%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (11)
3199 - Frankston - Peninsula Health Frankston Hospital (7)
6009 - Nedlands - Linear Clinical Research (6)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
5011 - Woodville South - The Queen Elizabeth Hospital (6)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
3168 - Clayton - Monash Medical Centre (4)
5042 - Bedford Park - Flinders Medical Centre (4)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
2170 - Liverpool - Liverpool Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
3004 - Melbourne, Southbank - Alfred Health (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
2605 - Garran - The Canberra Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
4032 - Chermside - The Prince Charles Hospital (2)
2109 - North Ryde - Macquarie University Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
6009 - Nedlands - One Clinical Research (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
3630 - Shepparton - Goulburn Valley Health (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (2)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3066 - Epping - Northern Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
6027 - Joondalup - Joondalup Health Campus (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
4350 - Toowoomba - Toowoomba Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2500 - Wollongong - Wollongong Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NA
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2228 - Miranda - Southside Cancer Care Centre (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Non-squamous non-small-cell lung cancer
Colorectal adenocarcinoma
Biliary tract cancer
Hepatobiliary cancer
Gastric cancer
Gastroesophageal cancer
Oesophageal adenocarcinoma
Oesophageal cancer
Endometrial cancer
Gynaecological cancer
Ovarian cancer
Sarcoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy